From GlobeNewswire: 2025-05-31 08:00:00

The Phase 1b trial follow-up on IMA203 PRAME cell therapy in metastatic melanoma patients shows promising clinical activity with deep and durable objective responses lasting over 2.5 years. Cutaneous melanoma patients had a cORR of 56%, mDOR of 12.1 months, mPFS of 6.1 months, and mOS of 15.9 months. Uveal melanoma patients, including tebentafusp-refractory patients, had a cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months. These positive results support the ongoing Phase 3 trial in advanced cutaneous melanoma and the expansion in uveal melanoma. ASCO presentations confirm Immatics’ leadership in precision targeting of PRAME. Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy shows favorable tolerability and promising clinical activity in 33 patients with metastatic melanoma. Results include cORR of 56%, mDOR of 12.1 months, and mPFS of 6.1 months. Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%, while uveal melanoma subgroup shows cORR of 67%. No Grade 5 events were observed, and patients demonstrated shrinkage of metastatic lesions. These positive results support the ongoing SUPRAME Phase 3 trial in advanced cutaneous melanoma and continued Phase 1b expansion in uveal melanoma. The trial aims to enroll over 360 patients and expects to complete enrollment by 2026. Phase 1b trial follow-up on IMA203 PRAME cell therapy in metastatic melanoma patients shows favorable tolerability and promising clinical activity with deep and durable objective responses. Cutaneous melanoma subgroup post-checkpoint inhibitor demonstrates positive results, while uveal melanoma subgroup shows high response rates. These results support the ongoing SUPRAME Phase 3 trial and Phase 1b expansion in uveal melanoma. Immatics’ PRAME franchise includes three product candidates targeting PRAME. IMA203 PRAME cell therapy is being evaluated in a Phase 3 trial for unresectable or metastatic cutaneous melanoma. Immatics combines target discovery with T cell receptor development for cancer immunotherapies.



Read more at GlobeNewswire: Immatics IMA203 PRAME Cell Therapy Data Presented at 2025